A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher.

Americans are having a few regrets about their approach to child safety in the care of drug-using parents.

Late last year, Health Canada approved lecanemab, a monoclonal antibody that clears amyloid plaques — a hallmark indicator of Alzheimer’s disease — in people with early-stage dementia while symptoms ...

Struggling with depression? NeuroStar TMS at Northeast Health Services offers safe, effective, FDA-cleared, non-drug ...

Disc Medicine is laying off about 20% of its workforce after the Food and Drug Administration denied its application for accelerated approval of its bitopertin treatment.

Neighborhood groups are mobilizing against any proposal that would bring supportive housing and addiction treatment to the campus.

An informational consumer overview of Zealthy's prescription hydroquinone program, including compounded medication status, FDA context, telehealth dermatology consultation details, subscription and ...

The Trump administration is proposing Obamacare plans that it says will lower health insurance premiums. But critics warn ...

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the drug developer's shares up nearly 42%, as it aims to win approval for the ...

Boston community leaders proposed a new plan to tackle the open-air drug market at and around Mass and Cass that focuses on ...

Public drug plans should not cover lecanemab, a drug to slow early-stage Alzheimer's disease, Canada's Drug Agency says in its draft recommendation.